RBC Capital Remains a Buy on GH Research (GHRS)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research (GHRS) with a $42 price target on August 6, noting the stock closed at $30.64. This aligns with a Strong Buy consensus and a Cantor Fitzgerald Buy rating ($40 target), suggesting significant upside potential for the healthcare sector stock.
RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed yesterday at $30.64.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. According to TipRanks, Abrahams has an average return of 14.3% and a 56.11% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GH Research with a $43.50 average price target, a 41.97% upside from current levels. In a report released on August 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $40.00 price target.